Table 4 Comparison of similar clinical studies.

From: Propensity score analysis of high-dose rate brachytherapy, immune checkpoint inhibitors, and docetaxel in second-line advanced NSCLC treatment

Study

Design

Therapy

Sample size

Result

TORG163023

Phase II/III

nivolumab + docetaxel

64

ORR: 41.8% mPFS: 6.7 m; mOS: 23.1 m

Wang et al.24

Phase II

nivolumab + docetaxel

22

ORR: 10.0% mPFS: 4.0 m; mOS: 10.0 m

PROLUNG25

Phase II

pembrolizumab + docetaxel

40

ORR: 42.5% mPFS: 9.5 m

Zhang et al.26

Retrospective

pembrolizumab/nivolumab + docetaxel

33

ORR: 31.8% mPFS: 7.5 m

Huang et al.27

Retrospective

pembrolizumab/nivolumab/Tislelizumab + rh-endostatin

40

ORR:20.8% mPFS: 7.1 m

Back to article page